First Clinical Trial Exploring Effects of a New, Immune System-Based Agent in Advanced Melanoma

facebook twitter google print email
Media Contact:Karen Kreeger | karen.kreeger@uphs.upenn.edu | 215-349-5658October 6, 2010

Researchers at the University of Pennsylvania School of Medicine and Immunocore Limited, Oxford, UK, today announced that a targeted agent that may have a role in treating advanced metastatic melanoma in the future has received Investigational New Drug (IND) approval and is opening enrollment for clinical trials in the UK and USA.

Click here to view the full release.

Multimedia